How Analysts Feel About Depomed, Inc. (NASDAQ:DEPO)?

June 18, 2018 - By reb123z

Depomed, Inc. (NASDAQ:DEPO) LogoInvestors sentiment increased to 1.36 in Q1 2018. Its up 0.43, from 0.93 in 2017Q4. It is positive, as 15 investors sold Depomed, Inc. shares while 40 reduced holdings. 29 funds opened positions while 46 raised stakes. 60.75 million shares or 8.72% more from 55.87 million shares in 2017Q4 were reported.
Monarch Ptnrs Asset Management Limited Liability has 0.02% invested in Depomed, Inc. (NASDAQ:DEPO). Engineers Gate Manager L P reported 90,809 shares. 34,734 are held by Cubist Systematic Strategies Llc. Jacobs Levy Equity Mgmt invested 0.01% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Dimensional Fund Advsr Limited Partnership has invested 0.01% in Depomed, Inc. (NASDAQ:DEPO). 777,344 are owned by Deutsche Commercial Bank Ag. Vanguard Gp Inc accumulated 4.51M shares. Globeflex L P owns 275,448 shares or 0.38% of their US portfolio. Blackrock owns 9.21 million shares. Voya Mgmt Limited Com invested 0% in Depomed, Inc. (NASDAQ:DEPO). Starboard Value Lp reported 4.54 million shares or 0.66% of all its holdings. Trexquant Invest Limited Partnership invested 0.01% of its portfolio in Depomed, Inc. (NASDAQ:DEPO). Zurcher Kantonalbank (Zurich Cantonalbank), a Switzerland-based fund reported 2,550 shares. Yakira Cap Mngmt reported 15,100 shares. Morgan Stanley accumulated 798,987 shares.

Since March 7, 2018, it had 0 insider buys, and 2 sales for $438,610 activity.

Depomed, Inc. (NASDAQ:DEPO) Ratings Coverage

Among 2 analysts covering Depomed (NASDAQ:DEPO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Depomed had 4 analyst reports since March 2, 2018 according to SRatingsIntel. The firm has “Buy” rating by Mizuho given on Friday, March 23. The firm has “Buy” rating given on Wednesday, May 16 by Mizuho. The stock has “Buy” rating by Roth Capital on Friday, March 2. The firm earned “Buy” rating on Thursday, May 10 by Mizuho. Below is a list of Depomed, Inc. (NASDAQ:DEPO) latest ratings and price target changes.

16/05/2018 Broker: Mizuho Rating: Buy New Target: $9.0000 Maintain
10/05/2018 Broker: Mizuho Rating: Buy New Target: $9.0000 Maintain
23/03/2018 Broker: Mizuho Rating: Buy New Target: $9.0000 Maintain
02/03/2018 Broker: Roth Capital Rating: Buy New Target: $10.0 Maintain

The stock increased 2.39% or $0.17 during the last trading session, reaching $7.29. About 602,038 shares traded. Depomed, Inc. (NASDAQ:DEPO) has declined 38.98% since June 18, 2017 and is downtrending. It has underperformed by 51.55% the S&P500.

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $463.55 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. It currently has negative earnings. The firm also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults.

More recent Depomed, Inc. (NASDAQ:DEPO) news were published by: Seekingalpha.com which released: “The Jury’s Still Out On Depomed” on May 21, 2018. Also Nasdaq.com published the news titled: “Depomed Announces the Appointment of Phillip B. Donenberg as Chief Financial Officer” on June 05, 2018. Nasdaq.com‘s news article titled: “Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: June 07, 2018 was also an interesting one.

Depomed, Inc. (NASDAQ:DEPO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: